title: Benefits of obstructive sleep apnoea treatment in coronary artery disease: a long-term follow-up study.
abstract: OBJECTIVE
  The aim of this long-term prospective study was to evaluate the effect of treating obstructive sleep apnoea (OSA) on the rate of cardiovascular events in coronary artery disease (CAD).
  
  
  RESULTS
  We prospectively studied 54 patients (mean age 57.3 +/- 10.1 years) with both CAD (> or = 70% coronary artery stenosis) and OSA (apnoea-hypopnoea index > or = 15). In 25 patients, OSA was treated with continuous positive airway pressure (n=21) or upper airway surgery (n=4); the remaining 29 patients declined treatment for their OSA. The median follow-up was 86.5 +/- 39 months. The two groups were similar at baseline in age, body mass index, smoking history, hypertension, hypercholesterolaemia, diabetes mellitus, number of diseased vessels, left ventricular ejection fraction, and CAD therapy. Treatment of risk factors other than OSA was similar in the two groups. The endpoint (a composite of cardiovascular death, acute coronary syndrome, hospitalisation for heart failure, or need for coronary revascularisation) was reached in 6 (6/25, 24%) and 17 (17/29, 58%) patients with and without OSA treatment, respectively (P<0.01). OSA treatment significantly reduced the risk of occurrence of the composite endpoint (hazard ratio 0.24; 95% confidence interval, 0.09-0.62; p<0.01) and of each of its components.
  
  
  CONCLUSIONS
  Our data indicate that the treatment of OSA in CAD patients is associated with a decrease in the occurrence of new cardiovascular events, and an increase in the time to such events.
authors.affiliation: Division of Cardiology, Ambroise Paré Teaching Hospital, AP-HP, UFR Paris-Ile de France-Ouest, Université de Versailles-Saint Quentin en Yvelines, 92104 Boulogne, France. olivier.milleron@apr.ap-hop-paris.fr
authors.forename: Olivier
authors.initials: O
authors.lastname: Milleron
authors.forename: Rémy
authors.initials: R
authors.lastname: Pillière
authors.forename: Arlette
authors.initials: A
authors.lastname: Foucher
authors.forename: Florence
authors.initials: F
authors.lastname: de Roquefeuil
authors.forename: Philippe
authors.initials: P
authors.lastname: Aegerter
authors.forename: Guillaume
authors.initials: G
authors.lastname: Jondeau
authors.forename: Bernadette G
authors.initials: BG
authors.lastname: Raffestin
authors.forename: Olivier
authors.initials: O
authors.lastname: Dubourg
mesh_terms: D015992:Body Mass Index; D023921:Coronary Stenosis / Q000209:etiology*; D003925:Diabetic Angiopathies / Q000150:complications; D018572:Disease-Free Survival; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D006937:Hypercholesterolemia / Q000150:complications; D006973:Hypertension / Q000150:complications; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D012307:Risk Factors; D020181:Sleep Apnea, Obstructive / Q000150:complications / Q000628:therapy*; D012907:Smoking / Q000009:adverse effects